Effect of Blue Light on Vagus Nerve Stimulation in Patients With Refractory Epilepsy

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Vagus nerve stimulation (VNS) is an adjunctive treatment for refractory epilepsy. Although widely used, there is still a substantial number of patients with insufficient response. Light, and particularly blue light, can stimulate alertness, attention and cognition through modulation of anatomical targets which are common to the vagal afferent network. This project aims at understanding how exposure to blue enriched light may influence VNS effects in patients with refractory epilepsy by exploring the modulation of a series of biomarkers of VNS action. This could possibly lead to new therapeutic strategies to increase efficacy of VNS.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 60
Healthy Volunteers: t
View:

• Patients:

• VNS implanted since at least 3 months age \>18-60 years; IQ \>55 on Wechsler scale (normal status or mild cognitive impairment)

• healthy participants aged between 18 and 35 years without any medical history (neurological / psychiatric disease)

Locations
Other Locations
Belgium
Cliniques Universitaires Saint Luc
RECRUITING
Woluwe-saint-lambert
Contact Information
Primary
Inci cakiroglu
inci.cakiroglu@uclouvain.be
+32470612917
Time Frame
Start Date: 2023-07-01
Estimated Completion Date: 2026-04
Participants
Target number of participants: 34
Treatments
Experimental: Patients with refractory epilepsy
Patients will not receive any drugs, but will participate to experiments involving electroencephalograpy, pupillometry and light administration.
Experimental: Healthy subjects
Subjects will not receive any drugs, but will participate to experiments involving electroencephalograpy, pupillometry and light administration.
Related Therapeutic Areas
Sponsors
Leads: Cliniques universitaires Saint-Luc- Université Catholique de Louvain

This content was sourced from clinicaltrials.gov